A5057635977- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Monoclonal and Polyclonal Antibodies Research
- Synthesis and Biological Evaluation
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Cancer Risks and Factors
- Peptidase Inhibition and Analysis
- Neutropenia and Cancer Infections
- Viral Infectious Diseases and Gene Expression in Insects
- Antifungal resistance and susceptibility
- Acute Lymphoblastic Leukemia research
- Central Venous Catheters and Hemodialysis
- Advancements in Semiconductor Devices and Circuit Design
- Calcium signaling and nucleotide metabolism
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cancer, Stress, Anesthesia, and Immune Response
- Immunodeficiency and Autoimmune Disorders
- Blood disorders and treatments
Bristol-Myers Squibb (United States)
2022-2024
University of Washington Medical Center
2016-2023
Fred Hutch Cancer Center
2016-2023
Seattle Cancer Care Alliance
2019-2021
Cancer Research Center
2017-2021
University of Washington
2019-2021
Thomas Jefferson University
2014-2019
Sidney Kimmel Cancer Center
2019
Einstein Medical Center Philadelphia
2014
Thomas Jefferson University Hospital
2014
BACKGROUND The clinical and procedural parameters that affect the optimal collection of lymphocytes for production chimeric antigen receptor (CAR) T cells remain undefined but are increasingly important, as commercial products now available. We evaluated determinants low lymphocyte efficiency (CE) rate successful CAR T‐cell manufacture in middle‐aged older adults with advanced B‐cell malignancies. STUDY DESIGNS AND METHODS Mononuclear cell collections using two apheresis platforms (COBE...
Autologous hematopoietic cell transplantation (AHCT) is a standard of care for several subtypes high-risk lymphoma, but durable remissions are not achieved in the majority patients. Intensified conditioning using CD45-targeted antibody-radionuclide conjugate (ARC) preceding AHCT may improve outcomes lymphoma by permitting delivery curative doses radiation to disease sites while minimizing toxicity. We performed sequential phase I trials escalating yttrium-90 (90Y)-labeled anti-CD45 antibody...
Since the introduction of lenalidomide into induction therapy for multiple myeloma (MM), there have been conflicting reports about its impact on autologous peripheral blood stem cell (PBSC) mobilization. We evaluated previous exposure in a large cohort patients with MM undergoing mobilization and collection at tertiary transplantation center. hypothesized that PBSCs is feasible even prolonged duration therapy. examined who attempted collection, seen our center between January 2012 July 2015....
Engraftment syndrome (ES) is a known complication of autologous hematopoietic stem cell transplant during neutrophil recovery. There limited amount data available comparing the incidence ES with post-transplant granulocyte colony-stimulating factor versus macrophage (GM-CSF), specifically in patients multiple myeloma. Our retrospective review 156 at single center showed that GM-CSF was associated higher compared G-CSF (32% 8% patients, P < .001) and development 32.9% (P longer hospital stay....
Introduction: High-dose melphalan and autologous stem cell transplantation (HDM/SCT) is an effective treatment modality for immunoglobulin light-chain (AL) amyloidosis; however, its application remains restricted to patients with good performance status limited organ involvement. In recent years, the paradigm AL amyloidosis has changed introduction of novel agents such as immunomodulatory drugs (IMiDs) proteasome inhibitors (PIs). We hypothesized that use agent induction regimens improved...
Engraftment syndrome (ES) is a complication of autologous hematopoietic progenitor cell transplantation (AHPCT) characterized by fever, rash, pulmonary, liver, and/or renal dysfunction. GM-CSF has been previously shown to be associated with higher risk ES as compared G-CSF after AHPCT in heterogeneous patient cohort. We the vs. exclusively multiple myeloma (MM) patients who received same conditioning regimen.
Allogeneic hematopoietic cell transplantation (allo-HCT) can be curative for relapsed or refractory B-cell lymphomas (BCLs), although outcomes are worse in aggressive disease, and most patients will still experience relapse. Radioimmunotherapy using 90Y-ibritumomab tiuxetan induce disease control across lymphoma subtypes a dose-dependent fashion. We hypothesized that megadoses of with reduced-intensity conditioning could safely produce deeper remissions BCL further maintained the immunologic...